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ABSTRACT
Objective: To examine the association between
exposure to newer antidepressants and risk of
gastrointestinal (GI) and other bleeding complications
among individuals with major depressive disorder
(MDD).
Design: This study uses an incident user cohort
design to compare associations between incidence of
vascular/bleeding events and the relative afﬁnity (low,
moderate or high) of the antidepressant for the
serotonin transporter during an exposure risk period
for each patient.
Setting: New England healthcare system electronic
medical record database.
Participants: 36389 individuals with a diagnosis of
MDD and monotherapy with a selective serotonin
reuptake inhibitor, serotoninenorepinephrine reuptake
inhibitor or other new-generation antidepressant were
identiﬁed from among 3.1 million patients in a New
England healthcare system.
Primary and secondary outcome
measures: Rates of bleeding or other vascular
complications, including acute liver failure, acute renal
failure, asthma, breast cancer and hip fractures.
Results: 601 GI bleeds were observed in the 21462
subjects in the high-afﬁnity group versus 333 among
the 14927 subjects in the lower afﬁnity group (adjusted
RR: 1.17, 95% CI 1.02 to 1.34). Similarly, 776 strokes
were observed in the high-afﬁnity group versus 434 in
the lower afﬁnity treatment group (adjusted RR: 1.18,
95% CI 1.06 to 1.32). No signiﬁcant association with
risk for a priori negative control outcomes, including
acute liver failure, acute renal failure, asthma, breast
cancer and hip fractures, was identiﬁed.
Conclusions: Use of antidepressants with high afﬁnity
for the serotonin transporter may confer modestly
elevated risk for GI and other bleeding complications.
While multiple methodologic limitations must be
considered, these results suggest that antidepressants
with lower serotonin receptor afﬁnity may be preferred
in patients at greater risk for such complications.
INTRODUCTION
Antidepressants are among the most widely
prescribed classes of medications in all of
medicine; over 255 million prescriptions for
antidepressants are issued annually, and this
number continues to increase.
1 Selective
serotonin reuptake inhibitors (SSRIs) and
other new-generation antidepressants are
generally preferred over older treatments
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ARTICLE SUMMARY
Article focus
- Previous reports have suggested that antide-
pressant use may contribute to dysfunction in
platelet aggregation and increased risk for
bleeding outcomes.
- The authors hypothesised that antidepressants
with higher afﬁnity for the serotonin transporter
would exhibit greater risk for these outcomes
than those with lesser afﬁnity.
Key messages
- Use of antidepressants with higher afﬁnity for the
serotonin transporter was associated with
modest but statistically signiﬁcant increase in
risk for gastrointestinal bleed and stroke.
- Electronic medical record-based pharmacovigi-
lance systems provide an opportunity to examine
treatment risk in general clinical populations, in
a more systematic fashion than traditional
postmarketing surveillance.
Strengths and limitations of this study
- A strength of this report, in addition to cohort
size and generalisability, is the restriction to
individuals with major depressive disorder,
minimising risk for confounding by indication.
- A key limitation is the absence of blood
antidepressant levels or data on adherence,
which might lead us to underestimate strength
of effect.
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Open Access Researchsuch as tricyclic antidepressants or monoamine oxidase
inhibitors on the basis of greater tolerability and safety.
2
Notwithstanding debates over the magnitude of beneﬁt,
their efﬁcacy in the treatment of major depressive
disorder has been established in numerous placebo- and
active-comparator studies over the past 2 decades.
2e4
While the precise mechanism of therapeutic action of
SSRIs is not known, their common mechanism of action
is inhibition of the serotonin transporter, responsible for
removal of serotonin from the synapse. Apart from its
central nervous system effects, serotonin is known to be
a vasoactive and thrombostatic amine.
5 Since the sero-
tonin transporter is also expressed in platelets, there has
been an active debate in the literature regarding the
effects of SSRIs on the vascular system. Multiple studies
suggest that SSRIs are generally safe in patients with
vascular disease
6 and have beneﬁcial effects in such
patients by decreasing platelet aggregation
78and by
vasodilation.
91 0Other studies, however, have associated
the use of SSRIs with increased incidence of vasospasm
and poor clinical outcomes after subarachnoid
haemorrhage
11 as well as increased mortality and poor
cardiovascular outcomes after coronary artery bypass
grafting.
12 Thus, while beneﬁcial in some contexts, the
peripheral effects of SSRIs and other serotonergic anti-
depressants might also be expected to confer increased
risk for vascular or bleeding complications.
In fact, several studies provide support for an
increased risk of upper GI bleeds in persons taking
SSRIs.
13e16 In patients treated with non-steroidal
inﬂammatory drugs (NSAIDs) or anticoagulants, the
addition of SSRI treatment is thought to increase the risk
of clinically relevant bleeds.
15 17e19 Likewise, while the
absolute risks are small,
20 21 SSRI use has also been
associated with an increased risk of ischaemic stroke
22e24
and haemorrhagic stroke,
20 though negative studies also
exist.
25 26
A key limitation in many of these studies is the difﬁ-
culty in adequately matching antidepressant-exposed
subjects with controls. This may contribute to
confounding by indication: that is, the same variables
(ie, depression and associated symptoms) which lead an
individual to be prescribed an antidepressant may
increase that individual’s risk of adverse outcomes. In
particular, psychological distress
27 and depression
28 have
been reported to be risk factors for cardiovascular
events. A recent large case-crossover study and a popu-
lation-based cohort study address some of these limita-
tions but do not fully address the substantial risk of
confounding by indication.
23 24 The need for further
characterisation of the relationship between SSRIs and
adverse bleeding events is apparent:
29 30 beyond the
need to conﬁrm such a relationship using a method-
ology less subject to confounding, the magnitude and
speciﬁcity of risk remains unclear.
Therefore, we adopted an alternative approach to
estimate risk associated with antidepressants, contrasting
those with highest afﬁnity for the serotonin transporter
with those of low or moderate afﬁnity. Based upon the
acute effects of these agents on platelet serotonin
transport, we hypothesised that high-afﬁnity agents
would be associated with greater risk of bleeding or
vascular events than lower afﬁnity ones. This approach
lessens risk of confounding by focusing only on
depressed antidepressant-treated patients, particularly as
clinicians typically do not consider afﬁnity per se when
selecting among the numerous available antidepressants.
We examined data from in- and outpatient medical
records for over 3 million individuals in a large New
England healthcare system.
METHODS
The Partners HealthCare electronic medical record
(EMR) incorporates sociodemographic data, billing
codes, laboratory results, problem lists, medications, vital
signs and narrative notes from Massachusetts General
Hospital and Brigham and Women’s Hospital, as well as
community and specialty hospitals which are part of the
Partners HealthCare System in Boston (Massachusetts,
USA). Altogether, these records comprise about 3.1
million unique patients.
Patients with the presence of at least one diagnosis of
major depression determined by the presence of Inter-
national Classiﬁcation of Diseases, 9th edition codes
(ICD-9 296.23, 296.33), in the billing data or outpatient
medical record were selected from the EMR for inclu-
sion in a data set (referred to as a data ‘mart’). The data
mart consists of all electronic records (psychiatric and
non-psychiatric) from 127504 patients and can be
utilised with the i2b2 server software (i2b2 v1.4).
31 The
present analysis included records from February 1990 to
October 2009. The i2b2 system
32 33 is a scalable
computational framework, deployed at over 46 major
academic health centres, for managing human health
data, and the i2b2 Workbench facilitates analysis and
visualisation of such data. The Partners Institutional
Review Board approved all aspects of this study.
Subjects were classiﬁed into groups based upon
documented antidepressant treatment from three
sources: (1) medications prescribed to the patient via e-
prescribing in the EMR, (2) medication documented but
not prescribed by the documenting clinician and (3)
medication dispensed by the inpatient pharmacy. The
three primary groups were labelled ‘high’, ‘moderate’
and ‘low’ afﬁnity for the serotonin transporter, based
upon previous work.
34 Classiﬁcation of newer antide-
pressants, including duloxetine and escitalopram, was
based upon Ki (table 1)
35e37din the case of escitalo-
pram, effective afﬁnity is greater than citalopram
because of the absence of the R enantiomer, which has
demonstrated antagonistic effects.
38e40 As reported
afﬁnities vary across publications,
37 41e44 we prioritised
comparative afﬁnities reported by a single laboratory
42
wherever possible and categories utilised in prior
studies employing similar methodology to this one.
35
Patients with multiple antidepressant prescriptions from
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as were those receiving tricyclic antidepressants or
monoamine oxidase inhibitors, out of concern that
these groups would not be well matched with those
receiving newer treatments and to avoid the known
cardiovascular risks associated with some older agents.
For initial analysis, the ‘high’-afﬁnity group was
contrasted with the other two groups to yield two simi-
larly sized cohorts for comparison, based on investigator
consensus and recognising that other groupings might
be equally reasonable. A further advantage of this
distinction was that it assigned duloxetine and venla-
faxine to different categories based on serotonin reup-
take afﬁnity, decreasing the likelihood of confounding
by non-serotonergic (ie, noradrenergic) effects. The
groups were ﬁrst compared in terms of sociodemo-
graphic features, including age, gender and race and
antidepressant use.
As electronic medical records data are not well suited
to standard survival analytic approaches, we utilised an
incident user cohort design to construct an exposure
risk period for each patient. This method was proposed
by Schneeweiss
45 speciﬁcally for pharmacovigilance
designs using electronic medical record and is concep-
tually related to prior approaches.
46 This approach has
previously demonstrated assay sensitivity in pharmacovi-
gilance studies using similarly structured data.
47 48 The
exposure period begins on the date an antidepressant
was prescribed and ends 30 days from prescription. If
a second prescription is documented in the 30-day
period, the period is extended another 30 days from this
prescription. Patient analysis is censored as soon as their
exposure risk period ends, that is, at the end of
a continuous documented period of exposure.
Outcomes occurring within any of the exposure periods
are included in the analysis. Logistic regression was used
to calculate crude RR, and RR was then adjusted for
person-months of exposure and other potential
confounding variables identiﬁed in the initial analysis of
baseline characteristics. To examine the importance of
this 30-day assumption, we also conducted a sensitivity
analysis as a means of determining if the length of the
exposure risk period had a meaningful impact on our
analysis. We re-ran the analysis for all the outcomes with
drug era windows of 60, 90 and 180 days. Adjusted RR
and CIs are provided in table S3.
Three sets of analysis were performed. First, we
examined associations between antidepressant group
and vascular/bleeding events (primary outcomes)
including gastrointestinal (GI) haemorrhage, myocar-
dial infarction and stroke. Follow-up analysis examined
each category of stroke (ischaemic or haemorrhagic)
separately. For consistency with prior reports, we also
conducted a secondary analysis on a subset of patients
with more conservative criteria for selecting patients with
major depressive disorder (MDD) (at lease two outpa-
tient diagnoses or at least one inpatient diagnosis). Next,
as a positive control or test for assay sensitivity, we
examined association between aspirin exposure and
GI bleed. Finally, as a negative control, we examined
associations between antidepressant group and ﬁve
outcomes selected by the clinical investigators (RHP,
JWS, DVI and IK) based upon literature review as likely
to be unrelated to serotonergic effects: acute liver
failure, acute renal failure, asthma, breast cancer and
hip fractures. Table S1 lists the ICD-9 codes used to
identify these outcomes of interest.
All analyses utilised R 2.13.1 (The R Foundation for
Statistical Computing).
RESULTS
Of 127504 individuals with MDD, 58690 (45%) received
at least one prescription for a newer antidepressant.
Thirty six thousand three hundred and eighty nine of
these patients were prescribed only one type of antide-
pressant, while 21851 individuals were prescribed anti-
depressants from different afﬁnity groups at any time
during the study period and were excluded from the
analysis (ﬁgure 1). Of the single group-treated patients,
14927 were treated with lowemoderate afﬁnity and
21462 with high afﬁnity, representing 44235 patient-
months of treatment in the lower group and 74706 in
the higher group. Table 2 shows associations between
treatment groups and baseline characteristics.
Compared with lowemoderate afﬁnity treatments,
patients with high-afﬁnity treatments were more likely to
be female, non-Caucasian and very slightly older
(difference in mean age between groups was <1 year).
They exhibited no signiﬁcant differences in total
number of prescription reﬁlls or overall utilisation of the
healthcare system (as measured by number of ‘facts’ in
the data mart, which include billing codes, medications,
procedures or other individual data points). Our
Table 1 Antidepressant afﬁnity groups by afﬁnity for
serotonin transporter*
Afﬁnity group Antidepressant
Inhibition
constant (Ki)
(mean±SD)
High Paroxetine 0.06560.006
Duloxetine (0.0760.01)y
Sertraline 0.2960.01
Escitalopram (0.7960.13)z
Fluoxetine 0.960.06
Moderate Citalopram 1.560.03
Fluvoxamine 1.660.1
Venlafaxine 7.560.4
Low Nefazodone 459628
Bupropion x
Mirtazapine x
*Adapted from Owens et al.
42
yKi drawn from Vaishnavi et al
37; relative order conﬁrmed in Martin
et al.
36 (J Pharmacol Exp Ther).
zKi drawn from Apparsundaram et al
35; relative order conﬁrmed in
Martin et al.
36 (J Pharmacol Exp Ther).
xNot reported; Tatsumi et al.
44 reports KD¼9100 for bupropion and
KD>10000 for mirtazapine (vs 200 for nefazodone).
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Antidepressant use and GI and other bleeding complications in MDDadjusted models therefore included age, gender, race
and aspirin use as covariates.
For a small subset of patients, depression severity
(assessed using the Quick Inventory of Depressive
Symptomatology-Self-Report
49) was available in the EMR
because the clinicians in some practices employ this
scale routinely. To address the possibility that our results
were confounded by severity, we examined depression
severity by afﬁnity group in an exploratory fashion. We
did not detect a signiﬁcant difference between groups as
measured by mean Quick Inventory of Depressive
Symptomatology-Self-Report score (L/M: 10.665.3, H:
10.365.3, p¼0.728) (table 2).
Figure 2 indicates adjusted RR and 95% CIs by treat-
ment group for outcomes of interest and negative
controls. RR signiﬁcantly >1 was observed in GI
haemorrhage (adjusted RR: 1.17, 95% CI 1.02 to 1.34)
and strokes (adjusted RR: 1.18, 95% CI 1.06 to 1.32)
between the lowemoderate and high-afﬁnity groups, but
not in myocardial infarctions (adjusted RR: 1.05, 95% CI
0.93 to 1.18). When stroke type (ischaemic or haemor-
rhagic) was examined, signiﬁcant effects were observed
for ischaemic strokes (adjusted RR: 1.20, 95% CI 1.06 to
1.35), but not haemorrhagic strokes (adjusted RR: 1.13,
95% CI 0.90 to 1.44). In the latter case, the point esti-
mate of effect was similar to that for all strokes, but the
smaller number of events yielded a broader CI.
Outcomes of interest for each antidepressant are listed
in table S2. A secondary analysis on a subset of patients
with more conservative criteria for selecting patients with
MDD yielded similar results (table S4).
As expected, aspirin exposure was also associated with
risk for GI bleed (crude RR: 12.3995, 95% CI 2.39 to
3.12). In a fully adjusted model including age, gender,
race, antidepressant treatment group, aspirin and treat-
ment group-by-aspirin interaction, no evidence of anti-
depressant treatment group-by-aspirin interaction was
observed (for interaction term, p¼0.630) (table 3).
In our analysis of negative control conditions with no
known or postulated associations to antidepressants, no
signiﬁcant associations with afﬁnity group were identi-
ﬁed (ﬁgure 2). These included both acute diagnoses
(acute renal failure, acute hepatic failure, hip fracture)
and chronic diagnoses (asthma, breast cancer).
In a sensitivity analysis examining the interval of risk
associated with antidepressant exposure, outcomes
within a 60-, 90-, or 180-day exposure window following
antidepressant prescription were examined. Results were
generally similar to those observed for the primary
analysis (table S3), persistently indicating elevated
risk for stroke and GI bleed but not for the control
conditions.
DISCUSSION
In this pharmacovigilance study using data from 127504
individuals with MDD in a single large healthcare
system, we identiﬁed a signiﬁcantly elevated risk for
GI haemorrhage and stroke when high-serotonin
transporter afﬁnity antidepressants were prescribed
compared with low-serotonin transporter afﬁnity anti-
depressants. No such effects were observed for other
general medical conditions selected a priori as negative
controls, suggesting that this association is less likely to
represent a non-speciﬁc effect of treatment.
Our results are consistent with prior reports which
detected a risk of GI bleed among SSRI-treated
patients.
15 17e19 24 For example, a large Scandinavian
population-based study found SSRI use to be associated
with 3.6-fold greater risk of upper GI bleed, an effect
potentiated by NSAID or aspirin use.
18 However, not all
such studies found this risk.
50 51 While most previous
studies compared antidepressant-treated patients to
untreated patients, with consequent risk of confounding
by indication, the present work minimises this risk by
comparing antidepressant treatments based on afﬁnity
for the serotonin transporter. Thus, presence of
depression alone cannot account for the observed
effects.
We also detected elevated risk for stroke in high-
afﬁnity antidepressant-treated patients. A similar point
estimate was identiﬁed when the analysis was limited to
individuals in whom the stroke type was characterised as
Figure 1 Study schematic.
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one. In light of the smaller number of events in this
analysis, as well as the potential for misclassiﬁcation in
diagnosis based on claims data, the difference
among haemorrhagic stroke patients is perhaps not
surprising. Previous studies have also suggested elevated
risk of stroke with SSRI or other antidepressant
treatment.
20 22 24 Data from the Women’s Health
Initiative found SSRI prescription to be associated with
elevated stroke risk after adjustment for other cardio-
vascular risk factors.
20 Likewise, a large population-based
cohort study of individuals age 65 or older found an
association between SSRI or other (non-tricyclic) anti-
depressant use and stroke risk compared with untreated
individuals.
24 Neither study, however, can fully exclude
confounding by indication.
On the other hand, a nested caseecontrol study
reported a lack of association between SSRI use and
haemorrhagic stroke,
25 and a case-crossover study like-
wise observed increased ischaemic but not haemorrhagic
stroke risk.
23 In light of these effects, the impact of
antidepressants might be better understood as dysregu-
lation of coagulation rather than simply an increase in
bleeding per se.
A notable advantage of EMR- or claims-based phar-
macovigilance studies is their potential to rapidly
identify risk that might otherwise go undetected in
randomised controlled trials. For example, a previous
study of rosiglitazone identiﬁed elevated risk of
myocardial infarction, before similar data from
prospective studies led the US FDA to consider with-
drawing that drug from the market.
47 Conﬁdence in our
Table 2 Characteristics of patients prescribed a newer antidepressant as deﬁned during 6 months prior to ﬁrst medication use
Lowemoderate afﬁnity
antidepressants* (n[14927)
High-afﬁnity
antidepressants* (n[21462) p Value
Demographic variables
Age (years), mean (SD) 51.8 (16.4) 52.6 (16.4) <0.001
Female gender 9965 (66.8) 15489 (72.2) <0.001
Race/ethnicityy <0.001
White 11423 (76.5) 16104 (75.0)
Black 873 (5.8) 1196 (5.6)
Hispanic 1183 (7.9) 2058 (9.6)
Asian 202 (1.4) 270 (1.3)
Other 1246 (8.3) 1834 (8.5)
Insurance <0.001
Private 7032 (47.1) 9779 (45.6)
Public 6082 (40.7) 8784 (40.9)
Other 1813 (12.1) 2899 (13.5)
Health system utilisation
Health facts per patient; median (IQR) 224 (95e483) 223 (91e477) 0.152
Years in health system; median (IQR) 10 (4e15) 10 (5e15)
Use of antidepressants
Reﬁlls per patient; median (IQR) 2 (1e4) 2 (1e5)
High afﬁnity
Duloxetine 1421 (7.0)
Escitalopram e 3254 (16.1)
Fluoxetine e 10648 (52.6)
Paroxetine e 6107 (30.2)
Sertraline e 10148 (50.1)
Moderate afﬁnity
Citalopram 8962 (56.2) e
Fluvoxamine 220 (1.4) e
Venlafaxine 3869 (24.2) e
Low afﬁnity
Nefazodone 473 (3.0) e
Bupropion 5792 (36.3) e
Mirtazapine 1621 (10.2) e
Exposure person-months 44235 74706
Depression severity (n¼136) n¼67 n¼69
QIDS-SR score; mean (SD) 10.6 (5.3) 10.3 (5.3) 0.728
Concomitant medications
Aspirin 4302 (28.8) 6095 (28.4) 0.721
*N (%), except otherwise indicated.
yRace and ethnicity are collected using a single ﬁeld in the electronic medical record, so subjects who identify as Hispanic are not further
characterised.
QIDS-SR, Quick Inventory of Depression Symptomatology-Self-Report.
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Antidepressant use and GI and other bleeding complications in MDDability to detect a ‘true’ signal using our methodology is
increased by the detection of association between aspirin
treatment and GI bleed, a well-known complication of
aspirin treatment, as well as by the negative ﬁndings
among the negative control diagnoses.
We note several limitations in considering our results.
First, we cannot exclude the possibility of residual
confounding arising from differences in the treatment
groups in this non-randomised cohort and speciﬁcally
the potential for biased assignment to one antidepres-
sant category. In general, most clinicians are unaware of
the differences in afﬁnity between SSRIs, so this would
be unlikely to inﬂuence clinical decision-making.
Among the low-afﬁnity antidepressants are primarily
non-SSRIs, which may be selected based upon some
clinical consideration. On the other hand, bupropion,
a low-afﬁnity antidepressant, is indicated for smoking
cessation and prescribed for depressed individuals who
smoke. Because smoking is a risk factor for stroke, one
would expect this low-afﬁnity antidepressant to be asso-
ciated with stroke risk, which would have an effect
opposing the one we observed. Similarly, non-SSRI
antidepressants are often second-line treatment
suggesting that individuals in the lower afﬁnity group
might be more treatment resistant and, therefore, at
greater risk for vascular complications. Because we
observed the opposite trend, it is unlikely that these
results are confounded by greater depression severity in
the high-afﬁnity group. Further, while depression
severity on a standardised scale was available only for
a small subset of individuals, that measure did not
support a confounding effect of severity.
Another limitation in the present analysis is the
inability to reliably characterise blood levels for indi-
vidual treatments, which in addition to afﬁnity will
determine extent of binding to serotonin transporter.
52
Many factors, including dose and adherence (including
unfulﬁlled prescriptions) and individual differences in
metabolism and concomitant medications will impact
blood level; correlation between individual characteristics
such as dosage and blood level may be modest.
53 These
sources of heterogeneity should be consistent across
treatment groups, however, so if anything we would
anticipate them to bias our results towards an absence
of association. Still, our results must be interpreted
cautiously with these restrictions in mind.
Table 3 Incidence rate and RR of bleed events and negative controls for users of lowemoderate serotonin afﬁnity
antidepressants compared with users of high-serotonin afﬁnity antidepressants
Outcome
Lowemoderate afﬁnity
antidepressant
High-afﬁnity
antidepressant RR (95% CI)
No. of
cases
Incidence rate
(per 1000
person-months)
No. of
cases
Incidence rate
(per 1000
person-months) Unadjusted Adjusted*
Primary outcomes
Gastrointestinal
haemorrhage
333 7.5 601 8.0 1.16 (1.02 to 1.29) 1.17 (1.02 to 1.34)
Stroke
All stroke 434 9.8 776 10.4 1.16 (1.03 to 1.30) 1.18 (1.06 to 1.32)
Ischaemic stroke 367 8.3 672 9.0 1.17 (1.04 to 1.33) 1.20 (1.06 to 1.35)
Haemorrhagic stroke 105 2.4 176 2.4 1.10 (0.87 to 1.40) 1.13 (0.90 to 1.44)
Myocardial infarction 387 8.7 630 8.4 1.04 (0.92 to 1.18) 1.05 (0.93 to 1.18)
Negative control events
Acute liver failure 382 8.6 611 8.2 1.00 (0.88 to 1.13) 1.01 (0.89 to 1.15)
Acute renal failure 363 8.2 542 7.3 0.94 (0.82 to 1.07) 0.95 (0.84 to 1.08)
Asthma 909 20.5 1350 18.1 0.96 (0.88 to 1.04) 0.94 (0.87 to 1.02)
Breast cancer 333 7.5 469 6.3 0.90 (0.79 to 1.04) 0.83 (0.73 to 0.96)
Hip fractures 71 1.6 113 1.5 0.99 (0.74 to 1.33) 0.95 (0.71 to 1.27)
*Adjusted for age, sex, race, aspirin use and exposure period.
Figure 2 Adjusted RR and 95% CIs for primary outcomes
and negative controls.
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Antidepressant use and GI and other bleeding complications in MDDNonetheless, our results add to a growing body of
evidence that some newer antidepressants may be asso-
ciated with elevated risks of GI bleeding and stroke. We
emphasise that these risks must be balanced against the
voluminous evidence of beneﬁt from treatment of
depression. Still, if conﬁrmed by further investigation, it
may be possible to achieve these beneﬁts while mini-
mising risk by selecting antidepressants with lesser
afﬁnity for the serotonin transporter. More broadly, our
results further indicate the potential utility of large
electronic medical record systems in understanding the
clinical risks of pharmacotherapy in psychiatry.
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